S-Alkyl and S-benzyl derivatives of glutathione are competitive inhibitors of glyoxalase I [6-81. These are synthesized by reacting reduced glutathione with the appropriate alkyl iodide or bromide, under basic conditions. They are purified readily by recrystallizing the crude product from ethanol or [8] and is the most effective S-aralkylglutathione inhibitor known. The difference in inhibitor potencies between the yeast and human enzymes reflects structural differences: the yeast enzyme has tyrosine and cysteine residues in the active site, whereas the human enzyme has tyrosine and tryptophan residues [l]. For S-benzylglutathione derivatives, aromatic substitution, which increases hydrophobic bonding with the enzyme, particularly in the para-position, has provided the most potent glyoxalase I inhibitors [ 121.
the hemithioacetal bind to the active site of glyoxalase I and are converted to enediolate intermediates followed by stereospecific protonation to form the thioester [4]. The active site of glyoxalase I contains a glutathione-recognition site, a general-base catalyst (thought to be the imidazole moiety of a histidine residue [S] ) and a proximate zinc ion, Zn2+, with co-ordinated water molecules that interact with the hemithioacetal and enediolate intermediate. The glutathione-recognition site is thought to form a complementary surface of counter-charged groups, lysine (mammalian enzyme) or arginine (yeast enzyme) residues and aspartate or glutamate residues, which bind the glutathionyl moiety of the hemithioacetal substrate by salt-bridge linkages 
Substrate analogue in hi bitors
S-Alkyl and S-benzyl derivatives of glutathione are competitive inhibitors of glyoxalase I [6-81. These are synthesized by reacting reduced glutathione with the appropriate alkyl iodide or bromide, under basic conditions. They are purified readily by recrystallizing the crude product from ethanol or [8] and is the most effective S-aralkylglutathione inhibitor known. The difference in inhibitor potencies between the yeast and human enzymes reflects structural differences: the yeast enzyme has tyrosine and cysteine residues in the active site, whereas the human enzyme has tyrosine and tryptophan residues [l] . For S-benzylglutathione derivatives, aromatic substitution, which increases hydrophobic bonding with the enzyme, particularly in the para-position, has provided the most potent glyoxalase I inhibitors [ 121.
Removing charged groups on the glutathionyl moiety of the S-alkylglutathione inhibitor, by esterification of the y-glutamyl and/or glycine residues S-Henzoxycarbonylglutathione derivatives also inhibit glyoxalase I: with the human enzyme, Sbenzoxycarbonylglutathione has a K , of 1.3 p M and S-p-nitrobenzoxycarbonylglutathione a K , of 3.1 p M [9, 111. These compounds were proposed to inhibit glyoxalase I1 only [ 151, but it appears now that they inhibit glyoxalase I as well.
Enediolate transition-state analogues
The active site of glyoxalase I is thought to represent a surface that is complementary in structure to Volume 
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Substitution
K, (PM)
Class of compound Name
Yeast Human 2-Hyd roxy-I ,4-nap ht hoq u i nones Lawsone H- (Table 2) .
2-Hydroxy-1,4-naphthoquinone derivatives are reversible, competitive inhibitors of glyoxalase I [ 161. Lapachol (2-hydroxy-3-isoprenyl-1,4-naphthoquinone) is the most potent inhibitor studied with K, values of 37.5 p M (yeast enzyme), 97.5 p M (ratliver enzyme) and 8.25 pM (human-red blood cell enzyme). 4 H-1 -Henzopyran-4-one (flavonoid) and 21-1-1 -benzopyran-2-one (coumarin) derivatives also inhibit glyoxalase I. The most effective compounds studied with the yeast enzyme were
quercetin, 3-hydroxyflavone and purpurogallin (all with K , = 9 p M ) [16, 171.
Product-analogue inhibitors
Oxygen ester analogues of the thioester product, S-I Aactoylglutathione, were prepared by acylating the protected tripeptide t-butoxycarbonyl-y-glutamylserylbenzylglycinate and subsequently deprotecting by solvolysis in trifluoroacetic acid and catalytic hydrogenolysis. Acetyl, propionyl, butyryl and valeryl derivatives of y-glutamyl-0-acylserylglycine were prepared. The inhibition of glyoxalase I increased with increasing acyl-group chain length.
For the yeast enzyme, the K, for y-glutamyl-0-valerylserylglycine was 4 12 pM [ 181.
Biological evaluation of glyoxalase I inhibitors
Inhibitors of glyoxalase I were proposed as novel anti-tumour agents by Vince and Daluge [19] . Inhibiting glyoxalase I was expected to lead to an increase in the cellular concentration of methylglyoxal to cytotoxic levels. Methylglyoxal had been shown previously to inhibit proliferation and to be toxic in tumour cells [20- It is probable that S-alkylglutathione derivatives, as was found for S-u-lactoylglutathione [26] , do not cross cell plasma membranes readily and so do not reach their intended receptor, glyoxalase I, in the cell cytosol. Moreover S-alkylglutathione derivatives are good substrates for y-glutamyltranspeptidase on the external surface of the plasma membrane [27] and are converted rapidly to Salkylcysteinylglycine derivatives and excreted by the mercapturic-acid pathway [28] . Vince et al. recognized this and tried to circumvent it by preparing glutaryl-S-(p-bromobenzyl)cysteinylglycine, which was resistant to cleavage by y-glutamyltranspeptidase, but was a poor inhibitor of glyoxalase I (Ki= 3.1 mM) [29] .
An alternative approach was to prepare the monoethyl ester of S-p-bromobenzylglutathione, y-glutamyl-S-pbromobenzylethylglycinate; Meister and co-workers have shown that the monoester of reduced glutathione was resistant to cleavage by y-glutamyltranspeptidase, crossed the plasma membrane of cells and was de-esterified intracellularly by a cytosolic non-specific esterase [30] . The S-p-bromobenzylglutathione monoethyl ester was synthesized by acid-catalysed esterification of S-pbromobenzylglutathione in ethanol [3 11 and was purified by chromatography on Dowex 1, formate form, with methanol as the eluent [9] . Th' IS was evaluated against HL60 and K562 cell cultures and had no effect on cell growth at concentrations 5 500 pM. However, the diethyl ester derivative, ethyl-yglutamyl-S-p-bromobenzylcysteinylethylglycinate, was prepared similarly and purified. S-p-Rromobenzylglutathione diethyl ester was found to induce growth arrest and to be toxic in HL60 cells and in K562 cells. The median growth inhibitory ICs, concentrations were 8.3 pM and 16.5 pM, respectively. There was decreased toxicity of the S-pbromobenzylglutathione diethyl ester to the corresponding differentiated cells: the ICjo for neutrophils was 40 p M and there was no significant toxicity to red blood cells at concentrations I 1 mM. The diethyl ester crosses the cell plasma membrane and is de-esterified within the cytosol successively to form the monoethyl ester and non-esterified derivatives [ 91. S-p-Bromobenzylglutathione generated in the cell cytosol may inhibit other glutathionedependent enzymes. S-Alkylglutathione derivatives inhibit glutathione reductase [ 321, glutathione transferase [33] and glyoxalase I1 [15, 34, 3 .51. The mechanism of growth arrest and toxicity in human leukaemia cells by S-pbromobenzylglutathione diethyl ester is currently unknown, but appears to be selective for proliferating cells, as is expected if the toxicity is mediated by methylglyoxal accumulation [36] . ( The inhibition of glyoxalase I1 may be excluded as a mechanism since S-p-bromobenzylglutathione and its ester derivatives did not inhibit glyoxalase I1 [9] .) However, it now appears that diethyl esterification of S-alkylglutathione substrateanalogue inhibitors of glyoxalase I is an effective modification to deliver the inhibitor to its putative cytosolic receptor.
Considering the other classes of glyoxalase I inhibitor mentioned, 2-hydroxyquinone derivatives may be generally cytotoxic [37] . The cytotoxity of some flavonoid and coumarin derivatives to tumour cells has been determined and, while some do have anti-tumour activity [38, 391, it is not clear that this correlates with the potency of glyoxalase I inhibition. Further synthesis and evaluation of flavonoid derivatives, however, may provide therapeutically valuable compounds.
S-pRromobenzylglutathione diethyl ester enters human red blood cells and is de-esterified intracellularly to S-p-bromobenzylglutathione. In 50% (v/v) suspensions of human red blood cells in culture, there was no significant toxicity induced by S-p-bromobenzylglutathione at concentrations 5 1 mM (S. J. Ridgway and P. J. Thornalley, unpub- lished results). Incubating S-p-bromobenzylglutathione diethyl ester (1-10 pM) with human red blood cells infected with the malarial parasite Plasmodium fakiparum led to selective toxicity to the parasite (R. J. M. Wilson and P. J. Thornalley, un- published results). The formation of I )-lactate is increased in parasite-infected red blood cells [ 401. It appears, therefore, that S-alkylglutathione diesters may be a novel class of anti-malarial agents.
With the potential of therapeutically useful Salkylglutathione di-esters, it is becoming increasingly important to optimize the interaction between S-alkylglutathione and the active site of glyoxalase I. The primary sequence and crystal structure of human glyoxalase I have not been determined yet Volume 
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and so little is known about the geometry of the active site. Quantitative structure-activity relationship studies have been carried out [41- We have been interested in glutathione recognition by proteins and have described generalized features of glutathione-binding sites previously [ 51.
W e report now the result of the use of a hydrophobic-cluster analysis and of hydropathy profiles, developed originally to screen for amphiphilic and transmembrane helices [6] . W e have identified regions of structural (and potentially functional) similarity between the glutathione-gated K+-efflux KefC protein, the cystic-fibrosis chloride-ion transporter and the multidrug resistance gene product.
Materials and methods
Sequence data were obtained through the SEQNET system and OWL database at the SERC Daresbury Abbreviations used: CFTK, cystic-fibrosis transmembrane receptor; ML)K, multidrug-resistance protein.
Facility [7] for sequence similarity searching.
Hydrophobic-cluster analysis was carried out using the method of Karran et al. [8] . All computing was carried out on a Silicon Graphics Iris-240 4D G T workstation operating under UNIX. Hydropathy profiles were generated using the algorithm of Kyte and Doolittle [9] .
Results and discussion
In our early studies of this system we felt that the hydrophobicity-cluster plots and the hydrophobicity profiles of KefC and of a number of other membrane-spanning proteins showed some similarity. One such transmembrane-protein superfamily is the ATP-binding cassette family that includes the cystic-fibrosis transmembrane-receptor gene (CFTR) and the multidrug-resistance protein (MDR). This class shows clear evidence of gene duplication, which is apparent from hydrophobicity-cluster analysis (results not shown) and from hydropathy-profile plots. The probable locations of the putative transmembrane helices of CFTR and MDR have been defined previously [lo] . These can be located unambiguously on the hydropathy plots as maxima and as large hydrophobic clusters in the cluster diagrams. The corresponding hydrophobicity clusters of KefC, CFTR and MDR provided the initial basis in our sequence alignment. The human CFTR sequence has 1480 residues; each half of the gene has a multiple-helix transmembrane region followed by a globular-like sequence containing an ATP-consensus motif of the form 'GXXXXGK[T,S]' [ 1 11. These C-terminal regions of the duplicated structure have been proposed to have a topology similar to that of adenylate kinase [lo] . The membrane-spanning region of CFTR is considered [ 101 to be composed of two sets of six transmembrane helices (M 1 -M6). Hetween the duplicated motifs there is a highly charged domain linking the two halves of the protein.
